Mandate

Vinge has advised KCG in connection with the acquisition of Neonet

September 16, 2016

Vinge has advised KCG Holdings, Inc. on its acquisition of Neonet Securities AB from inter alios Hay Tor Capital LLP, KAS Bank N.V., Nordic Capital / Cidron Delphi Intressenter AB and Neonet management. Neonet is a Swedish independent capital markets services provider offering a comprehensive suite of advanced algorithmic trading, smart order routing and sales.

KCG is a leading independent securities firm offering investors a range of services designed to address trading needs across asset classes, product types and time zones. The acquisition is a strategic supplement to KCG’s business concept and will strengthen KCG’s reach in continental Europe and will enable both KCG’s and Neonet’s clients to access a more complete range of international execution services and capabilities.

The acquisition was granted the relevant approvals from the Swedish Financial Supervisory Authority on 6 September and was completed on 14 September 2016.

Vinge’s team consisted of among others partners Daniel Rosvall (M&A) and Emma Stuart-Beck (Financial Services) as well as associates Samra Baytar (M&A), Caroline Krassén and Henrik Schön (Financial Services).


 

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024